Progenitor Cells and Clinical Outcomes in Patients with Heart Failure

Ayman Samman Tahhan, Muhammad Hammadah, Pratik B. Sandesara, Salim S. Hayek, Andreas P. Kalogeropoulos, Ayman Alkhoder, Heval Mohamed Kelli, Matthew Topel, Nima Ghasemzadeh, Kaavya Chivukula, Yi An Ko, Hiroshi Aida, Iraj Hesaroieh, Ernestine Mahar, Jonathan H. Kim, Peter Wilson, Leslee Shaw, Viola Vaccarino, Edmund K. Waller, Arshed A. Quyyumi

Research output: Contribution to journalArticlepeer-review


Background Endogenous regenerative capacity, assessed as circulating progenitor cell (PC) numbers, is an independent predictor of adverse outcomes in patients with cardiovascular disease. However, their predictive role in heart failure (HF) remains controversial. We assessed the relationship between the number of circulating PCs and the pathogenesis and severity of HF and their impact on incident HF events. Methods and Results We recruited 2049 adults of which 651 had HF diagnosis. PCs were enumerated by flow cytometry as CD45med+ blood mononuclear cells expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemokine (C-X-C motif) receptor 4 epitopes. PC subsets were lower in number in HF and after adjustment for clinical characteristics in multivariable analyses, a low CD34+ and CD34+/CXCR+ cell count remained independently associated with a diagnosis of HF (P<0.01). PC levels were not significantly different in reduced versus preserved ejection fraction patients. In 514 subjects with HF, there were 98 (19.1%) all-cause deaths during a 2.2±1.5-year follow-up. In a Cox regression model adjusting for clinical variables, hematopoietic-enriched PCs (CD34+, CD34+/CD133+, and CD34+/CXCR4+) were independent predictors of all-cause death (hazard ratio 2.0, 1.6, 1.6-fold higher mortality, respectively; P<0.03) among HF patients. Endothelial-enriched PCs (CD34+/VEGF+) were independent predictors of mortality in patients with HF with preserved ejection fraction only (hazard ratio, 5.0; P=0.001). Conclusions PC levels are lower in patients with HF, and lower PC counts are strongly and independently predictive of mortality. Strategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity in HF, especially, in HF with preserved ejection fraction, need to be further explored.

Original languageEnglish (US)
Article numbere004106
JournalCirculation: Heart Failure
Issue number8
StatePublished - Aug 1 2017
Externally publishedYes


  • cardiovascular outcomes
  • CD133
  • CD34
  • CXCR4
  • heart failure
  • progenitor cells
  • VEGF

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Progenitor Cells and Clinical Outcomes in Patients with Heart Failure'. Together they form a unique fingerprint.

Cite this